Sermorelin for women is a prescription question with a narrow evidence base. A small mixed-sex trial of a modified GHRH(1–29) analogue increased overnight growth hormone in 10 older women, but it did not improve women's lean mass, insulin sensitivity, well-being, libido or sleep. Studies limited to postmenopausal women used longer GHRH(1–44), not sermorelin itself. The useful conclusion is precise: the female pituitary can respond to GHRH signaling, but the data do not establish sermorelin as a treatment for menopause symptoms or a predictable body-composition therapy.
What sermorelin for women actually means
Sermorelin is the active 29-amino-acid fragment of growth-hormone-releasing hormone, or GHRH. It signals a responsive pituitary to release the body's own growth hormone. It does not supply growth hormone directly, and it does not replace estrogen or progesterone.
That distinction matters because three questions are often collapsed into one: whether the pituitary releases more growth hormone, whether the downstream marker IGF-1 changes, and whether a symptom or body-composition measure improves. A biochemical response answers only the first one or two. It does not guarantee the third.
The direct adult GHRH(1–29) studies by Corpas and Vittone that are frequently used to discuss sermorelin enrolled men, not women. Does sermorelin work? examines that overall evidence verdict, while sermorelin benefits covers outcome-by-outcome claims. The question here is narrower: what can legitimately be carried over to women?
What the studies actually show in women
The small female datasets do show pituitary responsiveness. They do not all study the same molecule, regimen or outcome, so their numbers are not interchangeable.
| Study | Women studied | What it found | Why the limit matters |
|---|---|---|---|
| Khorram, JCEM 1997 | 10 women and 9 men, ages 55–71 | A modified GHRH(1–29) analogue increased overnight GH in women; IGF-1 rose early in both sexes and skin thickness increased | Lean mass, insulin sensitivity, well-being and libido improved in men only; sleep did not improve in either sex |
| Bellantoni and Vittone, JCEM 1996 | 16 postmenopausal women, ages 49–75 | Older participants had a smaller GH response to a GHRH challenge than younger participants | This was an estrogen cross-over and stimulation study, not months of sermorelin treatment |
| Veldhuis, EJE 2005 | 10 postmenopausal women | Three months of GHRH(1–44) raised overnight GH by 98% and IGF-1 by 71%; visceral fat fell 16% from baseline | There was no parallel control group, the peptide was not sermorelin, and 70% had local skin reactions |
The Khorram trial is the closest mixed-sex evidence because it used a modified 1–29 peptide. Its sex-stratified results are the important part: women's GH output increased, yet the lean-mass, insulin-sensitivity, well-being and libido findings appeared only in men. Sleep quality was unchanged in both sexes.
The Veldhuis postmenopausal study is useful but further removed. It tested full-length GHRH(1–44), compared participants with their own baselines, and enrolled only 10 women. It also reported faster 30-metre walking and stair-climbing times, but no significant change in lean mass or strength. Those observations are a reason for further study, not a female sermorelin effect estimate.
Why CJC-1295 and ipamorelin are a separate choice
CJC-1295 with ipamorelin is another growth-hormone secretagogue strategy. The two components act through GHRH and ghrelin-receptor pathways, so the clinical reasoning is not identical to using short-acting sermorelin alone. There is no female head-to-head trial showing that the combination fills sermorelin's evidence gaps. A prescriber would need a separate rationale for choosing it rather than borrowing results from one product to support the other.
Sermorelin and menopause are separate questions
Growth-hormone secretion tends to fall with age in both sexes. Menopause arrives in the same part of life, and estradiol also interacts with the GH–IGF-1 axis. That overlap can make sleep disruption, recovery, body-composition change and low energy look like one hormonal problem when they may have several causes.
The details are more complicated than “estrogen falls, so GH falls.” In the Bellantoni and Vittone cross-over study, oral estrogen increased spontaneous GH secretion but neither oral nor transdermal estrogen restored the age-related reduction in GHRH-stimulated GH and IGF-1. Route also changed IGF-1 differently. This is why one lab value cannot diagnose the source of a midlife symptom.
Sermorelin is not hormone-replacement therapy. It does not replace ovarian hormones, and the trials above did not test hot flashes, genitourinary symptoms or fracture prevention as treatment endpoints. Menopause care and a sermorelin evaluation can coexist, but one should not be presented as a substitute for the other.
What a prescriber checks in a woman
A responsible review starts by checking whether the request matches the biology and whether another condition better explains the symptoms. Common decision points include:
- IGF-1 and the intended endpoint. IGF-1 is steadier than a random GH value, which may catch a pulse or a trough. A clinician interprets it against age, history and the reason treatment is being considered.
- Thyroid status. Untreated thyroid disease can affect symptoms and alter the GH axis, so it belongs in the differential before a response is attributed to sermorelin.
- Pregnancy and breastfeeding. These are exclusion questions because adequate current safety evidence is absent and historical sermorelin information contraindicated use during pregnancy or lactation.
- Cancer history. Active malignancy or an unresolved prior history requires particular caution because IGF-1 is a growth-signaling pathway; the provider may decline or require specialist input.
- Pituitary history and medications. Sermorelin depends on a pituitary that can respond, while some medicines and endocrine conditions can change that response.
The adverse-effect discussion belongs with sermorelin side effects. The prescribed amount and monitoring plan are individualized; sermorelin dosage explains how clinicians make those decisions without turning a published regimen into self-dosing instructions.
As of August 2026, Promise's sermorelin is dispensed as a compounded medication, which is different from an FDA-approved product: the formulation offered here is not FDA-approved. The FDA explains that compounded drugs do not undergo its premarket review for safety, effectiveness or quality. Regulatory status is one fact, not a marketing verdict: a licensed provider may still prescribe a compounded formulation when appropriate, and that decision is between the patient and the doctor.
A useful decision has a measurable goal
The evidence supports a measured conversation, not a menopause promise. A clinician can define the clinical reason for considering sermorelin, establish baseline information and decide what change would be meaningful enough to continue. At Promise, a licensed provider reviews every request and prescribes or declines on medical eligibility; not everyone qualifies. That accountable review matters most where female-specific evidence is this limited.